Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Shapiro

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 27, 2015
Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia AA D Shapiro, C Schoenig-Diesing, L Silvati-Fidell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 19, 2013
Variability in platelet- and collagen-binding defects in type 2M von Willebrand diseaseD M Larsen, S L Haberichter, J C Gill, et al.
Thrombosis and Haemostasis|May 1, 1995
Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study GroupG C White, A D Shapiro, E M Kurczynski, et al.
The American Journal of Pediatric Hematology/Oncology|November 1, 1993
Thrombosis in children receiving L-asparaginase. Determining patients at riskA D Shapiro, S L Clarke, J M Christian, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2006
The parachute must be properly folded S M Donfield, A D Shapiro, E D Gomperts, et al.
Thrombosis and Haemostasis|December 8, 1998
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgeryA D Shapiro, G S Gilchrist, W K Hoots, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical proceduresA D Shapiro, G C White Ii, H C Kim, et al.
Science (New York, N.Y.)|January 7, 1998
NDR1, a pathogen-induced component required for Arabidopsis disease resistanceK S Century, A D Shapiro, P P Repetti, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 21, 2013
Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registriesA D Shapiro, E J Neufeld, V Blanchette, et al.
Obstetrics and Gynecology|September 1, 1990
Postpartum intracranial venous thrombosis associated with dysfunctional protein C and deficiency of protein SK L Roos, R M Pascuzzi, M A Kuharik, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 27, 2015
Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia AA D Shapiro, C Schoenig-Diesing, L Silvati-Fidell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 19, 2013
Variability in platelet- and collagen-binding defects in type 2M von Willebrand diseaseD M Larsen, S L Haberichter, J C Gill, et al.
Thrombosis and Haemostasis|May 1, 1995
Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study GroupG C White, A D Shapiro, E M Kurczynski, et al.
The American Journal of Pediatric Hematology/Oncology|November 1, 1993
Thrombosis in children receiving L-asparaginase. Determining patients at riskA D Shapiro, S L Clarke, J M Christian, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2006
The parachute must be properly folded S M Donfield, A D Shapiro, E D Gomperts, et al.
Thrombosis and Haemostasis|December 8, 1998
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgeryA D Shapiro, G S Gilchrist, W K Hoots, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical proceduresA D Shapiro, G C White Ii, H C Kim, et al.
Science (New York, N.Y.)|January 7, 1998
NDR1, a pathogen-induced component required for Arabidopsis disease resistanceK S Century, A D Shapiro, P P Repetti, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 21, 2013
Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registriesA D Shapiro, E J Neufeld, V Blanchette, et al.
Obstetrics and Gynecology|September 1, 1990
Postpartum intracranial venous thrombosis associated with dysfunctional protein C and deficiency of protein SK L Roos, R M Pascuzzi, M A Kuharik, et al.
Pageof 8